Abstract:Huntington disease (HD) is a progressive autosomal dominant neurodegenerative disorder in which patients typically present with uncontrolled involuntary movements and subsequent cognitive decline. In 1993, a CAG trinucleotide repeat expansion in the coding region of the huntingtin (HTT) gene was identified as the cause of this disorder. This extended CAG repeat results in production of HTT protein with an expanded polyglutamine tract, leading to pathogenic HTT protein conformers that are resistant to protein turnover, culminating in cellular toxicity and neurodegeneration. Research into the mechanistic basis of HD has highlighted a role for bioenergetics abnormalities stemming from mitochondrial dysfunction, and for synaptic defects, including impaired neurotransmission and excitotoxicity. Interference with transcription regulation may underlie the mitochondrial dysfunction. Current therapies for HD are directed at treating symptoms, as there are no disease-modifying therapies. Commonly prescribed drugs for involuntary movement control include tetrabenazine, a potent and selective inhibitor of vesicular monoamine transporter 2 that depletes synaptic monoamines, and olanzapine, an atypical neuroleptic that blocks the dopamine D2 receptor. Various drugs are used to treat non-motor features. The HD therapeutic pipeline is robust, as numerous efforts are underway to identify disease-modifying treatments, with some small compounds and biological agents moving into clinical trials. Especially encouraging are dosage reduction strategies, including antisense oligonucleotides, and molecules directed at transcription dysregulation. Given the depth and breadth of current HD drug development efforts, there is reason to believe that disease-modifying therapies for HD will emerge, and this achievement will have profound implications for the entire neurotherapeutics field.

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

Progress in studies of gene therapy for Huntington's disease

Latest Advances on New Promising Molecular-Based Therapeutic Approaches for Huntington’s Disease

HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity

Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT

Gene Targeting Techniques for Huntington’s Disease

Lowering mutant huntingtin by small molecules relieves Huntington’s disease symptoms and progression

Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding

Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies

Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds

Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics

Advances in Gene and Cellular Therapeutic Approaches for Huntington’s Disease

Complex Pathogenesis and Therapeutic Strategies

A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity

Therapy development in Huntington disease: From current strategies to emerging opportunities

Protective role of downregulation in Huntington’s Disease models

HAP40 Modulates Mutant Huntingtin Aggregation and Toxicity in Huntington’s Disease Mice

Drugging unconventional targets: insights from Huntington's disease.

CRISPR-Based Genome-Editing Tools for Huntington’s Disease Research and Therapy

Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease

Suppression of MAPK11 or HIPK3 Reduces Mutant Huntingtin Levels in Huntington's Disease Models